結膜炎治療の世界市場-2022-2029

市場力学

新興国における結膜炎の蔓延が、予測期間中の世界市場を牽引する要因の一つです。また、性感染症（STD）の流行が急増していることも、予測期間中に世界市場を促進する要因のひとつと考えられます。衛生状態の悪化、早産、母親の性感染症などの要因は、新生児結膜炎のリスク要因の一部です。新興国におけるこの病気の治療に関する認知度の低さや、これらの国々における医薬品の適用範囲の狭さは、予測期間中の世界の新生児結膜炎治療市場を抑制する要因の一部となっています。

また、世界の主要都市で大気汚染が進んでいることも、市場を牽引しています。2021年に発表された世界銀行によると、大気汚染は約8兆1,000億米ドルの健康コストの原因となっており、世界GDPの6.1%に相当するとのことです。いくつかの先行研究により、環境大気汚染は結膜炎やアレルギー性結膜炎を悪化させることが証明されています。これは、結膜が環境中の微粒子に対して敏感であることと、結膜が外部環境と直接接触することに起因しています。したがって、大気汚染の増加が世界の結膜炎治療市場の推進力となっています。

C. Michael Gibson教授は、2020年にConjunctivitis epidemiology and demographicsを発表し、ウイルス性結膜炎は一般的に大人がかかり、細菌性結膜炎は子どもがかかると述べています。感染性結膜炎の発症率は、1歳未満（患者10万人あたり8,000人）の方が4歳未満（患者10万人あたり1,200人）より高いです。この病気は非常にありふれたものであり、その治療も容易に行えます。また、この病気は自己診断が可能な場合がほとんどで、診断検査を受ける必要はほとんどありません。

インドのような国でも、結膜炎の有病率は高くなっています。例えば、2020年2月2日、タミルナドゥ州は、学校の生徒や職員の間でウイルス性結膜炎の問題が発生していると通達しました。

また、病気やその治療に関する人々の意識の高まりも、市場を後押ししています。いくつかの州では、結膜炎の治療を積極的に推進しています。治療薬の入手が容易なことも、市場を後押ししています。可処分所得の増加も予測期間中の市場成長を後押ししています。

しかし、今後数年間は特許の崖に直面することが予想されます。費用対効果の高い特定のジェネリック医薬品が入手可能であることが、市場の成長を大きく阻害する可能性があります。前臨床試験や臨床試験に利用可能な新規化合物の不足が、市場の成長に影響を与えています。パイプラインにある医薬品や細菌性結膜炎の承認に関する調査が少ないことが、予測期間中の市場成長に影響を及ぼしています。

さらに、世界中でCOVID-19のパンデミックが発生したことは、世界市場の成長に悪影響を及ぼすと考えられています。結膜炎を患っている患者は、通常アデノウイルスのために引き起こされるウイルス性結膜炎にかかるリスクが高い傾向にあるにもかかわらず、市場は減少に向かうと予想されます。コロナウイルスは、結膜炎の感染、水様性分泌物、羞明、眼刺激など、いくつかの同様の眼症状や徴候を引き起こしますが、アデノウイルスは、結膜炎の感染、水様性分泌物、羞明、眼刺激など、眼症状や徴候を引き起こすことがあります。

世界各国の政府による厳格な閉鎖措置により、命に別条はないもの受診が延期またはキャンセルされるため、この時期には結膜炎の処方箋が発行されることは少なく、市場の成長が制限されると予想されます。この要因は、予測期間中の市場成長を阻害するでしょう。

地域別プレゼンテーション

結膜炎治療市場は、地域別に北米、南米、欧州、アジア太平洋、中東・アフリカに区分されます。すべての地域の中で、北米は世界の結膜炎治療市場を独占し、結膜炎治療市場で事業を展開する多数の主要企業の存在により、予測期間中に最高のCAGRで成長すると予想されます。

国立衛生研究所によると、結膜炎は毎年、米国全体で600万人以上が罹患しているとされています。この疾患の推定コストは、年間約3億7,700万米ドルから8億5,700万米ドルです。結膜炎は同国で最も頻度の高い疾患で、人口の15%から40%が罹患し、春から夏にかけて頻繁に見られることが分かっています。米国では医療サービスが充実しており、結膜炎に罹患する人が多いことから、予測期間において最大のシェアを占めると予想されます。米国喘息・アレルギー財団によると、毎年5,000万人以上の人々が様々な種類のアレルギーを経験しています。この5,000万人のうち、米国では約650万人が急性結膜炎に罹患していると推定されています。このような要因が、地域全体の市場成長を促進すると期待されています。

アジア太平洋地域は、感染症の流行、発展途上国の劣悪な衛生環境、地域内の一部の国における長時間の分娩の増加により、3番目に大きなシェアを有すると予想されます。さらに、インド、中国、マレーシアなどの国々では、医療観光産業が活況を呈しており、治療に対する需要が高まると予想されます。これらの要因が、同地域における予測期間中の市場成長を刺激しています。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

• 疾患タイプ別市場内訳
• 薬物クラス別市場内訳
• エンドユーザー別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 結膜炎を患う人の増加
    • 治療薬の入手のしやすさ
  • 抑制要因
    • 家庭薬などの代替治療法の入手性
• 影響分析
• 機会

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 法規制分析
• 価格設定分析
• 製品分析
• COVID-19影響度分析

第6章 疾患タイプ別

• アレルギー性結膜炎
• 細菌性結膜炎
• ウイルス性結膜炎

第7章 薬物クラス別

• 抗生物質
• 眼科用ステロイド剤
• 非ステロイド性抗炎症薬（NSAIDS）
• 抗ヒスタミン薬
• その他

第8章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• 南米
  • .エンドユーザー別市場規模分析および前年比成長率分析（%）（単位：百万円
    • ブラジル
    • アルゼンチン
    • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第11章 企業プロファイル

• Boehringer Ingelheim GmbH
  • 企業概要
  • 製品ポートフォリオと説明
  • 主な発展状況
  • 財務概要
• Allergan Inc.
• Sanofi-Aventis
• Novartis AG
• Bausch & Lomb Inc.
• CIBA Vision Ophthalmics
• Pfizer Inc.
• Merck & Co., Inc.
• Santen Pharmaceuticals Co. Ltd.
• Akron Incorporated（*List is not exhaustive）

第12章 重要考察

第13章 データムインテリジェンス

Market Overview

The Conjunctivitis Treatment market was valued at USD 3,750.60 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 3.88% during the forecast period (2022-2029).

Conjunctivitis is a common condition that causes redness and inflammation of the thin layer of tissue that covers the front of the eye. It can be highly contagious. But it's rarely serious. It's very unlikely to damage the vision. Conjunctivitis caused by some bacteria and viruses can spread easily from person to person, but it isn't a serious health risk if diagnosed promptly. If it happens in a newborn baby, though, tell a doctor right away, as it might be an infection that threatens the baby's vision.

Allergies are also a common cause of conjunctivitis. The cells in the conjunctiva can react to an allergen. Some examples of allergens include grass, dust, animal fur, and mascara. Both viral and bacterial conjunctivitis can occur along with colds or symptoms of a respiratory infection, such as a sore throat. Other symptoms of conjunctivitis include itchiness and watering of the eyes, and sometimes a sticky coating on the eyelashes.

Conjunctivitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae requires aggressive antibiotic therapy, but conjunctivitis due to other bacteria is usually self-limited. Chronic conjunctivitis is usually associated with blepharitis, recurrent styes, or meibomianitis. Treatment requires good eyelid hygiene and the application of topical antibiotics as determined by culture. Allergic conjunctivitis is distinguished by severe itching and allergen exposure.

Market Dynamics

The market is driven is the increasing prevalence of conjunctivitis in developing countries is one of the factors driving the global market during the forecast period. The surge in the prevalence of sexually transmitted diseases (STDs) is another factor likely to propel the global market during the forecast period. Factors such as poor hygiene conditions, premature deliveries, and maternal sexually transmitted infection are some of the risk factors for neonatal conjunctivitis. Lack of awareness about the treatment of the disease in developing countries and lack of coverage of medicines in these countries are some of the factors restraining the global neonatal conjunctivitis treatment market during the forecast period.

The market is also driven by rising air pollution in major cities across the globe. According to the world bank published in 2021, Air pollution is responsible for health costs of around 8.1 trillion US$, equivalent to 6.1 percent of the global GDP. Some earlier research studies have proven that ambient air pollution can aggravate conjunctivitis and allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of the conjunctiva with the outside environment. Hence, the rise in air pollution propels the global conjunctivitis treatment market.

Professor C. Michael Gibson M.S., M.D, has published Conjunctivitis epidemiology and demographics, in 2020, viral conjunctivitis commonly affects adults, and bacterial conjunctivitis affects children. The incidence of infective conjunctivitis is higher in children less than 1-year-old (8,000 cases per 100,000 patients) than in children less than 4 years of age (1,200 cases per 100,000 patients). The disease is very common, and treatment for the same is easily available. Most of the time, the disease is self-diagnosable, and there is least need to undergo any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. For instance, on 2nd February 2020, Tamil Nadu state notified that viral conjunctivitis problem among the student and staff in school.

A rise in awareness among people about the disease and its treatment is also boosting the market. Several states are actively promoting the treatment of the disease. Easy availability of the treatment is boosting the market. The rise in disposable income is also driving the growth of the market in the forecast period.

However, the market is expecting to face a patent cliff in the coming years. The availability of certain cost-effective generic medicines is likely to hamper the market growth extensively. The scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of the market. The dearth of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline is affecting the market growth in the forecast period.

Moreover, the outbreak of the COVID-19 pandemic across the globe is set to negatively impact the global market growth. Despite the patients suffering from conjunctivitis tend to be at a high risk of getting injected by viral conjunctiva that is usually caused because of adenovirus, the market is expected to undergo a decline. While coronavirus also causes several similar ocular signs and symptoms, such as conjunctivitis infection, watery discharge, photophobia, and eye irritation.

Due to the stringent lockdowns imposed by governments across the globe, the postponement or cancellations of non-life-threatening medical visits is expected to restrict the market growth as lesser prescriptions for conjunctivitis will be issued in this period. This factor will hamper the market growth in the forecast period.

Market Segmentation:

The global conjunctivitis treatment market is segmented based on disease type into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment held the largest market share. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.

As stated by the Asthma and Allergy Foundation of America, approximately 30% of adults and 40% of children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust. This factor will drive the growth of the market in the forecast period.

Moreover, the National Institutes of Health (NIH) indicated that the number of patients being diagnosed with allergic conjunctivitis is increasing globally. This increase in incidence rate propels the global allergic conjunctivitis treatment market. Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of a clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two-third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors are driving the growth of the market in the forecast period.

The bacterial conjunctivitis segment is expected to have positive market growth in the forecast period. Bacterial conjunctivitis is one of the major eye problems encountered worldwide and are caused by bacteria such as Moraxella and Chlamydia trachomatis. These bacteria are responsible for causing persistent conjunctivitis with a higher level of redness. Most of the cases of bacterial conjunctivitis are acute and self-limiting and not a major cause of serious health problems however, due to its high prevalence the infection can have a large impact on society as individuals tend to miss their school or work.

The increasing cases of bacterial conjunctivitis demand efficient medication, which supports the growth of the bacterial conjunctivitis drugs market. Bacterial conjunctivitis spreads because of poor hygiene, immune compromise, and ocular diseases such as dry eye, blepharitis, and contaminated cosmetics. It can be prevented by maintaining proper hygiene and also hand wash reduces the chances of bacterial conjunctivitis. This factor will drive the growth of the market in the forecast period.

Further, the market is also classified based on drug class as antibiotics, ophthalmic steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antihistamines, others. The antibiotics segment is held the largest market share. Antibiotics may help shorten the length of infection, reduce complications, and reduce the spread to others. Antibiotics may be necessary for people whose immune system is compromised. In certain cases where an underlying infection elsewhere in the body may be causing conjunctivitis symptoms, you may be prescribed antibiotics to swallow in tablet form. Standard antibiotic treatments often will work for ordinary bacterial infections related to staphylococcus (staph) or streptococcus (strep) infections, which are the usual causes of bacterial conjunctivitis in adults. This factor will drive the growth of the market in the forecast period.

Typical antibiotic treatment often will work for these types of bacterial infections without the need to swab the eye and send off a sample (culture) for evaluation. If the initial treatment doesn't work, then a culture may be needed so that treatment can be changed to a more specialized type of antibiotic.

Geographical Presentation

By region, the conjunctivitis treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global conjunctivitis treatment market and is expected to grow at the highest CAGR during the forecast period due to the presence of a large number of key players operating in the conjunctivitis treatment market.

According to the National Institute of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer. Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the forecast period. According to the Asthma and Allergy Foundation of America, more than 50 million people experienced with various types of allergies in every year. In the 50 million people, estimated approximately around 6.5 million people that acute conjunctivitis affects in the United States. These factors are expected to fuel the overall market growth across the region.

The Asia-Pacific region is expected to have the third-largest share due to an increase in the prevalence of infections, poor hygiene conditions in developing countries, and prolonged deliveries in some of the countries in the region. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia are expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region.

Competitive Landscape:

The conjunctivitis treatment market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Novartis AG, Bausch & Lomb Inc., CIBA Vision Ophthalmic, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the conjunctivitis treatment market across the globe.

For instance, On 25th February 2021, Allergan, an AbbVie company, submitted its new drug application for investigational AGN-190584 for the Treatment of Presbyopia. The most common treatment-emergent non-serious adverse events occurring at a frequency of ≥5% in AGN-190584 treated participants were headache and conjunctival hyperemia.

On 30th June 2022, Novartis acquired the Kedalion Therapeutics AcuStream platform, a topical ocular delivery device used to facilitate dosing support and the delivery of front-of-eye therapies.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Disease Type
• 3.2. Market Snippet by Drug Class
• 3.3. Market Snippet by End users
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Number of People Suffering From Conjunctivitis
    • 4.1.1.2. Easy Availability of the Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Availability of Alternative Treatments Such as Home Remedies
• 4.2. Impact Analysis
• 4.3. Opportunity

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Product Analysis
• 5.6. COVID-19 Impact Analysis

6. By Disease Type

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
• 6.3. Market Attractiveness Index, By Disease Type
  • 6.3.1. Allergic Conjunctivitis *
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
  • 6.3.2. Bacterial Conjunctivitis
  • 6.3.3. Viral Conjunctivitis

7. By Drug Class

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
• 7.3. Market Attractiveness Index, By Disease
  • 7.3.1. Antibiotics
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
  • 7.3.2. Ophthalmic Steroids
  • 7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 7.3.4. Antihistamines
  • 7.3.5. Others

8. By End-users

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users Market Attractiveness Index, By End-users
  • 8.2.1. Hospitals
  • 8.2.2. Introduction
  • 8.2.3. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 9.3. Market Attractiveness Index, By Region
• 9.4. North America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. U.S.
    • 9.4.6.2. Canada
    • 9.4.6.3. Mexico
• 9.5. Europe
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. Germany
    • 9.5.6.2. U.K.
    • 9.5.6.3. France
    • 9.5.6.4. Rest of Europe
• 9.6. South America
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.5. . Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
  • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.6.6.1. Brazil
    • 9.6.6.2. Argentina
    • 9.6.6.3. Rest of South America
• 9.7. Asia Pacific
  • 9.7.1. Introduction
  • 9.7.2. Key Region-Specific Dynamics
  • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),End-users
  • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.7.6.1. China
    • 9.7.6.2. India
    • 9.7.6.3. Japan
    • 9.7.6.4. Australia
    • 9.7.6.5. Rest of Asia Pacific
• 9.8. Middle East and Africa
  • 9.8.1. Introduction
  • 9.8.2. Key Region-Specific Dynamics
  • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Boehringer Ingelheim GmbH *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Developments
  • 11.1.4. Financial Overview
• 11.2. Allergan Inc.
• 11.3. Sanofi-Aventis
• 11.4. Novartis AG
• 11.5. Bausch & Lomb Inc.
• 11.6. CIBA Vision Ophthalmics
• 11.7. Pfizer Inc.
• 11.8. Merck & Co., Inc.
• 11.9. Santen Pharmaceuticals Co. Ltd.
• 11.10. Akron Incorporated(*List is not exhaustive)

12. Premium Insights

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us